TreeFrog Therapeutics is a French biotechnology company focused on developing scalable manufacturing solutions for cell therapies. The company's proprietary C-Stem technology platform uses innovative microcarriers and 3D cell culture systems to dramatically increase the production capacity of therapeutic cells, particularly pluripotent stem cells. TreeFrog's technology addresses one of the major bottlenecks in cell therapy commercialization - the ability to manufacture therapeutic cells at scale and at acceptable costs. The company works with pharmaceutical partners to enable large-scale production of cell-based therapeutics.
TreeFrog Therapeutics has received investment from 1 venture capital firm.
Biotech company developing scalable cell therapy manufacturing technologies using innovative 3D cell culture and microcarrier systems.
TreeFrog Therapeutics has received investment from Kurma Partners. These venture capital firms and investors provide both capital and strategic support.
TreeFrog Therapeutics has raised $82M in total funding, with their most recent round being a Series B. The company operates in the Biotech sector.
TreeFrog Therapeutics was founded in 2018 and is headquartered in Bordeaux, France.
TreeFrog Therapeutics operates in the Biotech sector. Biotech company developing scalable cell therapy manufacturing technologies using innovative 3D cell culture and microcarrier systems.
